Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01344226 · ClinicalTrials.gov registry record
Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
A clinical trial, sponsored by Toyos Clinic.
- Completed
- Registry status
- 49
- Enrollment target
NCT01344226: Completed study, sponsored by Toyos Clinic.
NCT01344226 is a clinical trial that has completed, run by Toyos Clinic. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01344226 has completed, sponsored by Toyos Clinic.
- COMPLETED
- Registry status
- 49 participants
- Enrollment target
Study Summary
Investigate the intraocular pressure(pressure inside the eye) of patients who are treated with Lotemax after undergoing cataract surgery.
Primary Outcome
Evaluate intraocular pressure change in mm Hg from baseline in the first 6 weeks following cataract surgery in individuals treated with Lotemax (loteprednol ophthalmic solution) 0.5% QID after cataract extraction with posterior chamber intraocular implantation.
Interventions
- DRUG loteprednol 0.5% ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-09 |
What the finished NCT01344226 record still lists
NCT01344226 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 49 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which loteprednol 0.5% ophthalmic solution is the first listed.
NCT01344226 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01344226 about?
NCT01344226 is a clinical study titled "Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery". Investigate the intraocular pressure(pressure inside the eye) of patients who are treated with Lotemax after undergoing cataract surgery.
What is the current status of trial NCT01344226?
This trial is currently completed. The enrollment target is 49 participants. The study started on 2011-04. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01344226?
The interventions under investigation include: loteprednol 0.5% ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT01344226?
This trial is sponsored by Toyos Clinic, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia